Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.33 EUR | -4.90% | -2.65% | -17.71% |
Mar. 11 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
Mar. 05 | Medicus Pharma Names COO | MT |
Sales 2021 | 28.79M 31.08M | Sales 2022 | 25.74M 27.79M | Capitalization | 97.31M 105M |
---|---|---|---|---|---|
Net income 2021 | 38M 41.03M | Net income 2022 | -44M -47.51M | EV / Sales 2021 | 2.79 x |
Net cash position 2021 | 3.61M 3.9M | Net cash position 2022 | 4.88M 5.26M | EV / Sales 2022 | 3.59 x |
P/E ratio 2021 |
2.18
x | P/E ratio 2022 |
-1.98
x | Employees | 92 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.74% |
Latest transcript on Biofrontera AG
1 day | -1.44% | ||
1 week | +15.28% | ||
Current month | -2.25% | ||
1 month | +1.17% | ||
3 months | -14.95% | ||
6 months | -36.91% | ||
Current year | -13.47% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 55 | 22-09-11 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 21-12-13 | |
Director/Board Member | - | 21-12-13 | |
Heikki Lanckriet
BRD | Director/Board Member | 47 | 21-12-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.33 | -4.90% | 14 426 |
24-03-27 | 0.347 | +1.46% | 11,628 |
24-03-26 | 0.342 | 0.00% | 4,887 |
24-03-25 | 0.342 | 0.00% | 1,500 |
24-03-22 | 0.342 | +0.88% | 100 |
Delayed Quote Xetra, March 28, 2024 at 04:02 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.47% | 23.96M | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.17% | 210B | |
+1.64% | 210B | |
-7.08% | 201B | |
-3.51% | 157B |